The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

A positive feedback loop of heparanase/syndecan1/nerve growth factor regulates cancer pain progression

  • Xiaohu, Su (Department of Anesthesiology, Suqian First People's Hospital) ;
  • Bingwu, Wang (Cancer Institute, The Second Affiliated Hospital of Xuzhou Medical University) ;
  • Zhaoyun, Zhou (Department of Anesthesiology, Tai'an Central Hospital) ;
  • Zixian, Li (Department of Anesthesiology, Graduate School of Xuzhou Medical University) ;
  • Song, Tong (Department of Anesthesiology, Graduate School of Xuzhou Medical University) ;
  • Simin, Chen (Department of Anesthesiology, Graduate School of Xuzhou Medical University) ;
  • Nan, Zhang (Department of Anesthesiology, Graduate School of Xuzhou Medical University) ;
  • Su, Liu (Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University) ;
  • Maoyin, Zhang (Department of Anesthesiology, The Affiliated Hospital of Xuzhou Medical University)
  • Received : 2022.08.10
  • Accepted : 2022.10.22
  • Published : 2023.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: The purpose of this research was to assess the role of heparanase (HPSE)/syndecan1 (SDC1)/nerve growth factor (NGF) on cancer pain from melanoma. Methods: The influence of HPSE on the biological function of melanoma cells and cancer pain in a mouse model was evaluated. Immunohistochemical staining was used to analyze HPSE and SDC1. HPSE, NGF, and SDC1 were detected using western blot. Inflammatory factors were detected using ELISA assay. Results: HPSE promoted melanoma cell viability, proliferation, migration, invasion, and tumor growth, as well as cancer pain, while SST0001 treatment reversed the promoting effect of HPSE. HPSE up-regulated NGF, and NGF feedback promoted HPSE. High expression of NGF reversed the inhibitory effect of HPSE down-regulation on melanoma cell phenotype deterioration, including cell viability, proliferation, migration, and invasion. SST0001 down-regulated SDC1 expression. SDC1 reversed the inhibitory effect of SST0001 on cancer pain. Conclusions: The results showed that HPSE promoted melanoma development and cancer pain by interacting with NGF/SDC1. It provides new insights to better understand the role of HPSE in melanoma and also provides a new direction for cancer pain treatment.

Keywords

Acknowledgement

This study was supported by the project of experimental study on the role of Heparanase/Syndecan1/NGF signaling pathway and its positive feedback characteristics in the occurrence and development of cancer pain (BK20181153).

References

  1. Neufeld NJ, Elnahal SM, Alvarez RH. Cancer pain: a review of epidemiology, clinical quality and value impact. Future Oncol 2017; 13: 833-41. https://doi.org/10.2217/fon-2016-0423
  2. Lovell M, Agar M, Luckett T, Davidson PM, Green A, Clayton J. Australian survey of current practice and guideline use in adult cancer pain assessment and management: perspectives of palliative care physicians. J Palliat Med 2013; 16: 1403-9. https://doi.org/10.1089/jpm.2013.0245
  3. Magee D, Bachtold S, Brown M, Farquhar-Smith P. Cancer pain: where are we now? Pain Manag 2019; 9: 63-79. https://doi.org/10.2217/pmt-2018-0031
  4. Sanderson RD, Elkin M, Rapraeger AC, Ilan N, Vlodavsky I. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS J 2017; 284: 42-55. https://doi.org/10.1111/febs.13932
  5. Rivara S, Milazzo FM, Giannini G. Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases. Future Med Chem 2016; 8: 647-80. https://doi.org/10.4155/fmc-2016-0012
  6. Doweck I, Feibish N. Opposing effects of heparanase and heparanase-2 in head & neck cancer. Adv Exp Med Biol 2020; 1221: 847-56. https://doi.org/10.1007/978-3-030-34521-1_37
  7. Hermano E, Goldberg R, Rubinstein AM, Sonnenblick A, Maly B, Nahmias D, et al. Heparanase accelerates obesity-associated breast cancer progression. Cancer Res 2019; 79: 5342-54. https://doi.org/10.1158/0008-5472.can-18-4058
  8. Heyman B, Yang Y. Mechanisms of heparanase inhibitors in cancer therapy. Exp Hematol 2016; 44: 1002-12. https://doi.org/10.1016/j.exphem.2016.08.006
  9. Jiang X, Tian Y, Xu L, Zhang Q, Wan Y, Qi X, et al. Inhibition of triple-negative breast cancer tumor growth by electroacupuncture with encircled needling and its mechanisms in a mice xenograft model. Int J Med Sci 2019; 16: 1642-51. https://doi.org/10.7150/ijms.38521
  10. Demir IE, Tieftrunk E, Schorn S, Friess H, Ceyhan GO. Nerve growth factor & TrkA as novel therapeutic targets in cancer. Biochim Biophys Acta 2016; 1866: 37-50. https://doi.org/10.1016/j.bbcan.2016.05.003
  11. Wang W, Chen J, Guo X. The role of nerve growth factor and its receptors in tumorigenesis and cancer pain. Biosci Trends 2014; 8: 68-74. https://doi.org/10.5582/bst.8.68
  12. Di Donato M, Cernera G, Migliaccio A, Castoria G. Nerve growth factor induces proliferation and aggressiveness in prostate cancer cells. Cancers (Basel) 2019; 11: 784. https://doi.org/10.3390/cancers11060784
  13. Hayakawa Y, Sakitani K, Konishi M, Asfaha S, Niikura R, Tomita H, et al. Nerve growth factor promotes gastric tumorigenesis through aberrant cholinergic signaling. Cancer Cell 2017; 31: 21-34. https://doi.org/10.1016/j.ccell.2016.11.005
  14. Han L, Jiang J, Xue M, Qin T, Xiao Y, Wu E, et al. Sonic hedgehog signaling pathway promotes pancreatic cancer pain via nerve growth factor. Reg Anesth Pain Med 2020; 45: 137-44. https://doi.org/10.1136/rapm-2019-100991
  15. Teixeira FCOB, Gotte M. Involvement of Syndecan-1 and heparanase in cancer and inflammation. Adv Exp Med Biol 2020; 1221: 97-135. https://doi.org/10.1007/978-3-030-34521-1_4
  16. Jayatilleke KM, Hulett MD. Heparanase and the hallmarks of cancer. J Transl Med 2020; 18: 453. https://doi.org/10.1186/s12967-020-02624-1
  17. Sayyad MR, Puchalapalli M, Vergara NG, Wangensteen SM, Moore M, Mu L, et al. Syndecan-1 facilitates breast cancer metastasis to the brain. Breast Cancer Res Treat 2019; 178: 35-49. https://doi.org/10.1007/s10549-019-05347-0
  18. Chute C, Yang X, Meyer K, Yang N, O'Neil K, Kasza I, et al. Syndecan-1 induction in lung microenvironment supports the establishment of breast tumor metastases. Breast Cancer Res 2018; 20: 66. https://doi.org/10.1186/s13058-018-0995-x
  19. Calixto-Campos C, Correa MP, Carvalho TT, Zarpelon AC, Hohmann MS, Rossaneis AC, et al. Quercetin reduces Ehrlich tumor-induced cancer pain in mice. Anal Cell Pathol (Amst) 2015; 2015: 285708. https://doi.org/10.1155/2015/285708
  20. Pellati F, Borgonetti V, Brighenti V, Biagi M, Benvenuti S, Corsi L. Cannabis sativa L. and nonpsychoactive cannabinoids: their chemistry and role against oxidative stress, inflammation, and cancer. Biomed Res Int 2018; 2018: 1691428. https://doi.org/10.1155/2018/1691428
  21. Masola V, Zaza G, Gambaro G, Franchi M, Onisto M. Role of heparanase in tumor progression: molecular aspects and therapeutic options. Semin Cancer Biol 2020; 62: 86-98. https://doi.org/10.1016/j.semcancer.2019.07.014
  22. Hermano E, Meirovitz A, Meir K, Nussbaum G, Appelbaum L, Peretz T, et al. Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme. J Natl Cancer Inst 2014; 106: dju332. https://doi.org/10.1093/jnci/dju332
  23. Vlodavsky I, Singh P, Boyango I, Gutter-Kapon L, Elkin M, Sanderson RD, et al. Heparanase: from basic research to therapeutic applications in cancer and inflammation. Drug Resist Updat 2016; 29: 54-75. https://doi.org/10.1016/j.drup.2016.10.001
  24. Ramani VC, Zhan F, He J, Barbieri P, Noseda A, Tricot G, et al. Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget 2016; 7: 1598-607. https://doi.org/10.18632/oncotarget.6408
  25. Hao NB, Tang B, Wang GZ, Xie R, Hu CJ, Wang SM, et al. Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K/Akt/NF-κB signaling pathway for gastric cancer metastasis. Cancer Lett 2015; 361: 57-66. https://doi.org/10.1016/j.canlet.2015.02.043
  26. Luan Q, Sun J, Li C, Zhang G, Lv Y, Wang G, et al. Mutual enhancement between heparanase and vascular endothelial growth factor: a novel mechanism for melanoma progression. Cancer Lett 2011; 308: 100-11. https://doi.org/10.1016/j.canlet.2011.04.019
  27. Wei RR, Sun DN, Yang H, Yan J, Zhang X, Zheng XL, et al. CTC clusters induced by heparanase enhance breast cancer metastasis. Acta Pharmacol Sin 2018; 39: 1326-37. https://doi.org/10.1038/aps.2017.189
  28. Barash U, Lapidot M, Zohar Y, Loomis C, Moreira A, Feld S, et al. Involvement of heparanase in the pathogenesis of mesothelioma: basic aspects and clinical applications. J Natl Cancer Inst 2018; 110: 1102-14. https://doi.org/10.1093/jnci/djy032
  29. Ramani VC, Vlodavsky I, Ng M, Zhang Y, Barbieri P, Noseda A, et al. Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype. Matrix Biol 2016; 55: 22-34. https://doi.org/10.1016/j.matbio.2016.03.006
  30. Renz BW, Takahashi R, Tanaka T, Macchini M, Hayakawa Y, Dantes Z, et al. β2 adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. Cancer Cell 2018; 33: 75-90.e7. Erratum in: Cancer Cell 2018; 34: 863-7. https://doi.org/10.1016/j.ccell.2018.10.010
  31. Salvo E, Tu NH, Scheff NN, Dubeykovskaya ZA, Chavan SA, Aouizerat BE, et al. TNFα promotes oral cancer growth, pain, and Schwann cell activation. Sci Rep 2021; 11: 1840. https://doi.org/10.1038/s41598-021-81500-4
  32. Lin H, Huang H, Yu Y, Chen W, Zhang S, Zhang Y. Nerve growth factor regulates liver cancer cell polarity and motility. Mol Med Rep 2021; 23: 288. https://doi.org/10.3892/mmr.2021.11927
  33. Garrido MP, Torres I, Avila A, Chnaiderman J, Valenzuela-Valderrama M, Aramburo J, et al. NGF/TRKA decrease miR-145-5p levels in epithelial ovarian cancer cells. Int J Mol Sci 2020; 21: 7657. https://doi.org/10.3390/ijms21207657
  34. Faulkner S, Griffin N, Rowe CW, Jobling P, Lombard JM, Oliveira SM, et al. Nerve growth factor and its receptor tyrosine kinase TrkA are overexpressed in cervical squamous cell carcinoma. FASEB Bioadv 2020; 2: 398-408. https://doi.org/10.1096/fba.2020-00016
  35. Parimon T, Brauer R, Schlesinger SY, Xie T, Jiang D, Ge L, et al. Syndecan-1 controls lung tumorigenesis by regulating miRNAs packaged in exosomes. Am J Pathol 2018; 188: 1094-103. https://doi.org/10.1016/j.ajpath.2017.12.009
  36. Binder Gallimidi A, Nussbaum G, Hermano E, Weizman B, Meirovitz A, Vlodavsky I, et al. Syndecan-1 deficiency promotes tumor growth in a murine model of colitis-induced colon carcinoma. PLoS One 2017; 12: e0174343. https://doi.org/10.1371/journal.pone.0174343
  37. Zhang Y, Wang Z, Liu J, Zhang S, Fei J, Li J, et al. Cell surface-anchored syndecan-1 ameliorates intestinal inflammation and neutrophil transmigration in ulcerative colitis. J Cell Mol Med 2017; 21: 13-25. Erratum in: J Cell Mol Med 2017; 21: 834. https://doi.org/10.1111/jcmm.12934
  38. Ibrahim SA, Gadalla R, El-Ghonaimy EA, Samir O, Mohamed HT, Hassan H, et al. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. Mol Cancer 2017; 16: 57. https://doi.org/10.1186/s12943-017-0621-z
  39. Yang Y, Tao X, Li CB, Wang CM. MicroRNA-494 acts as a tumor suppressor in pancreatic cancer, inhibiting epithelial-mesenchymal transition, migration and invasion by binding to SDC1. Int J Oncol 2018; 53: 1204-14. https://doi.org/10.3892/ijo.2018.4445
  40. Yu S, Lv H, Zhang H, Jiang Y, Hong Y, Xia R, et al. Heparanase-1-induced shedding of heparan sulfate from syndecan-1 in hepatocarcinoma cell facilitates lymphatic endothelial cell proliferation via VEGF-C/ERK pathway. Biochem Biophys Res Commun 2017; 485: 432-9. https://doi.org/10.1016/j.bbrc.2017.02.060